Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193491 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation of IPI-493 in Hematologic Malignancies
A Phase 1 study, sponsored by Infinity Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01193491 is a Phase 1 study that was terminated before completion, run by Infinity Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT01193491, a Phase 1 study, was terminated before completion, sponsored by Infinity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
Interventions
- DRUG IPI-493
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01193491
The ClinicalTrials.gov registry entry for NCT01193491 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-493 is the first listed.
NCT01193491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01193491 about?
NCT01193491 is a clinical study titled "Dose Escalation of IPI-493 in Hematologic Malignancies". The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
What is the current status of trial NCT01193491?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2010-06. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01193491?
The interventions under investigation include: IPI-493 (DRUG).
Who is sponsoring clinical trial NCT01193491?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.